Showing results (161-170 of 187) with videos related to

Sort By:
Pageof 19
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 8, 2023
Perioperative TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer: APOLLO-11 studyDaisuke Takahari, Hitoshi Katai, Atsuo Takashima, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|November 12, 2020
Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis (P1a): a multi-institutional retrospective studyToshifumi Yamaguchi, Atsuo Takashima, Kengo Nagashima, et al.
European Journal of Cancer (Oxford, England : 1990)|July 25, 2021
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trialTadamichi Denda, Atsuo Takashima, Makio Gamoh, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 28, 2024
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trialYoon-Koo Kang, Min-Hee Ryu, Maria Di Bartolomeo, et al.
Translational Oncology|June 26, 2023
A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancerHiroki Osumi, Atsuo Takashima, Akira Ooki, et al.
Cancer Science|February 6, 2021
Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancerShin Takahashi, Yasuhiro Sakamoto, Tadamichi Denda, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|November 8, 2020
A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group study (JCOG1009/1010)Kohei Takizawa, Hiroyuki Ono, Noriaki Hasuike, et al.
British Journal of Cancer|March 4, 2023
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trialYasutoshi Kuboki, Tetsuji Terazawa, Toshiki Masuishi, et al.
Japanese Journal of Clinical Oncology|August 30, 2024
Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study groupAtsuo Takashima, Megumi Ishiguro, Keita Sasaki, et al.
International Journal of Clinical Oncology|December 16, 2019
Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS studyToshikazu Moriwaki, Shota Fukuoka, Toshiki Masuishi, et al.
Pageof 19